Advances in Heart Failure: A Year of Discovery - Moving Forward with SGLT-2 Inhibitors

PART 1: SGLT-2 inhibitors: Where Are We Now?

Learning objectives

  • Evaluate emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM
  • Interpret the new data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM in relationship to the existing data.
  • Understand the implementation of the emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM for clinical practice.

 


Programme Outline
  • PART 1: SGLT-2 inhibitors: Where Are We Now?Andrew JS CoatsHarriette Van SpallFaiez Zannad
  • PART 2: SGLT2 Inhibitors in HFrEF: EMPEROR-ReducedAndrew JS CoatsHarriette Van SpallFaiez Zannad
  • PART 3: SGLT-2 Inhibitors in ContextAndrew JS CoatsHarriette Van SpallFaiez Zannad
Supported by an unrestricted educational service from Boehringer Ingelheim

PART 2: SGLT2 Inhibitors in HFrEF: EMPEROR-Reduced